{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:39:27Z","timestamp":1793338767588,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"ANR Emergence","doi-asserted-by":"publisher","award":["ANR-12-EMMA-0011-01"],"award-info":[{"award-number":["ANR-12-EMMA-0011-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur Accelerating Preclinical Candidates \u2013 GPF \u2013 Vaccinology 2015","doi-asserted-by":"publisher","award":["GPFVacc2-08"],"award-info":[{"award-number":["GPFVacc2-08"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.vaccine.2018.11.022","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T14:06:28Z","timestamp":1542636388000},"page":"123-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-1645","authenticated-orcid":false,"given":"Christian E.","family":"Demeure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Derbise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Guillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cauchemez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Carniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pizarro-Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.11.022_b0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199709043371004","article-title":"Multidrug resistance in Yersinia pestis mediated by a transferable plasmid","volume":"337","author":"Galimand","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.11.022_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3201\/eid0701.010106","article-title":"Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis","volume":"7","author":"Guiyoule","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.022_b0015","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weapon \u2013 medical and public health management","volume":"283","author":"Inglesby","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2018.11.022_b0020","doi-asserted-by":"crossref","first-page":"e0004162","DOI":"10.1371\/journal.pntd.0004162","article-title":"Complete protection against pneumonic and bubonic plague after a single oral vaccination","volume":"9","author":"Derbise","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.11.022_b0025","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/nrm932","article-title":"The Yersinia YSC-YOP 'type III' weaponry","volume":"3","author":"Cornelis","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0030","unstructured":"Food Drug Administration CfDER. 21CFR601 \u2013 Biologics \u2013 Part 601: Licencing. Subpart H: Approval of biological products when human efficacy studies are not ethical or feasible. In: FDA, editor. FDA Maryland; 2017."},{"key":"10.1016\/j.vaccine.2018.11.022_b0035","unstructured":"Food Drug Administration CfDER. 21CFR314 \u2013 Drugs for Human Use \u2013 Part 314: Applications for FDA approval to market a new Drug \u2013 Subpart I: Approval of New Drugs when Human Efficacy Studies are not Ethical or Feasible. In: FDA, editor. FDA Maryland; 2017."},{"key":"10.1016\/j.vaccine.2018.11.022_b0040","unstructured":"Office of Regulatory Affairs. Guidance Document \u2013 Submission and Information Requirements for Extraordinary Use New Drugs (EUNDs). In: Health-Canada, editor. Ottawa; 2014."},{"key":"10.1016\/j.vaccine.2018.11.022_b0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1740774515619860","article-title":"A viewpoint on European Medicines Agency experience with investigational medicinal products for Ebola","volume":"13","author":"Cavaleri","year":"2016","journal-title":"Clin Trials"},{"key":"10.1016\/j.vaccine.2018.11.022_b0050","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.11.022_b0055","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1016\/j.vaccine.2008.09.063","article-title":"Antibodies and cytokines independently protect against pneumonic plague","volume":"26","author":"Kummer","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0060","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1128\/IAI.73.11.7304-7310.2005","article-title":"Cell-mediated protection against pulmonary Yersinia pestis infection","volume":"73","author":"Parent","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.022_b0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/14760584.7.2.209","article-title":"Current challenges in the development of vaccines for pneumonic plague","volume":"7","author":"Smiley","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.11.022_b0070","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.vaccine.2008.01.033","article-title":"Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague","volume":"26","author":"Zauberman","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0075","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.vaccine.2009.10.143","article-title":"Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice","volume":"28","author":"Little","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0080","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1128\/CVI.00290-15","article-title":"Characterization of a cynomolgus macaque model of pneumonic plague for evaluation of vaccine efficacy","volume":"22","author":"Fellows","year":"2015","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.11.022_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2249.1999.00859.x","article-title":"An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model","volume":"116","author":"Williamson","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tim.2006.10.004","article-title":"Cell-mediated immunity and the challenges for vaccine development","volume":"14","author":"Salerno-Goncalves","year":"2006","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0095","first-page":"e1528","article-title":"An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague","volume":"6","author":"Derbise","year":"2012","journal-title":"PLoS NTD"},{"key":"10.1016\/j.vaccine.2018.11.022_b0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/356154a0","article-title":"Targeted disruption of mu chain membrane exon causes loss of heavy-chain allelic exclusion","volume":"356","author":"Kitamura","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.11.022_b0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0140-6736(03)12270-2","article-title":"Development and testing of a rapid diagnostic test for bubonic and pneumonic plague","volume":"361","author":"Chanteau","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.11.022_b0110","first-page":"1627","article-title":"S\u00e9rodiagnostic des infections humaines \u00e0 Yersinia pathog\u00e8nes","volume":"25","author":"Benoit","year":"1996","journal-title":"Presse M\u00e9d"},{"key":"10.1016\/j.vaccine.2018.11.022_b0115","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/IAI.58.9.2840-2849.1990","article-title":"Secretion of Yop proteins by Yersiniae","volume":"58","author":"Michiels","year":"1990","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.022_b0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4049\/jimmunol.91.2.179","article-title":"Biosynthesis and purification of V and W antigens in Pasteurella pestis","volume":"91","author":"Lawton","year":"1963","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1574-695X.2010.00687.x","article-title":"The search for early markers of plague: evidence for accumulation of soluble Yersinia pestis LcrV in bubonic and pneumonic mouse models of disease","volume":"59","author":"Flashner","year":"2010","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0130","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4049\/jimmunol.1003303","article-title":"IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection","volume":"186","author":"Lin","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0135","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/CVI.00398-06","article-title":"Development of in vitro correlate assays of immunity to infection with Yersinia pestis","volume":"14","author":"Bashaw","year":"2007","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.11.022_b0140","series-title":"Yersinia, systems biology and control","first-page":"123","article-title":"Acellular vaccines against plague","author":"Williamson","year":"2012"},{"key":"10.1016\/j.vaccine.2018.11.022_b0145","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.vaccine.2004.01.007","article-title":"A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice","volume":"22","author":"Morton","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0150","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/IAI.72.9.5502-5505.2004","article-title":"Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine","volume":"72","author":"Mencher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.022_b0155","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.1997.56.471","article-title":"Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis","volume":"56","author":"Anderson","year":"1997","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.11.022_b0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-695X.1995.tb00196.x","article-title":"A new improved sub-unit vaccine for plague: the basis of protection","volume":"12","author":"Williamson","year":"1995","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0165","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-3083.2010.02456.x","article-title":"Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta","volume":"72","author":"Qiu","year":"2010","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0170","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1128\/IAI.00105-08","article-title":"Yersinia pestis caf1 variants and the limits of plague vaccine protection","volume":"76","author":"Quenee","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.022_b0175","series-title":"National Institutes of allergy and infectious diseases, NIH volume 1, frontiers in research","first-page":"473","article-title":"Correlates of Immunity Elicited by Live Yersinia pestis Vaccine","author":"Braciale","year":"2008"},{"key":"10.1016\/j.vaccine.2018.11.022_b0180","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1128\/IAI.02173-14","article-title":"LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague","volume":"82","author":"Sun","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.022_b0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.micinf.2007.10.003","article-title":"Antibody profiling in plague patients by protein microarray","volume":"10","author":"Li","year":"2008","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2018.11.022_b0190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.chom.2008.09.004","article-title":"Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis","volume":"4","author":"DePaolo","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2018.11.022_b0195","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","article-title":"Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine","volume":"16","author":"Heath","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0200","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/infdis\/129.Supplement_1.S13","article-title":"Plague immunization. I. Past and present trends","volume":"129","author":"Meyer","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.022_b0205","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ni0504-460","article-title":"Vaccine development strategies for improving immunization: the role of modern immunology","volume":"5","author":"Levine","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/IAI.61.1.23-31.1993","article-title":"Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha","volume":"61","author":"Nakajima","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.022_b0215","unstructured":"PublicHealthEngland. Live attenuated vaccines: avoid use in those who are clinically immunosuppressed. In: GOV.UK, editor. Vigilance, safety alerts and guidance; 2016."},{"key":"10.1016\/j.vaccine.2018.11.022_b0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2017.03.011","article-title":"Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis","volume":"80","author":"Lopez","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2018.11.022_b0225","unstructured":"Pitt L. Nonhuman Primates as a Model for Pneumonic Plague. Public workshop on animal models and correlates of protection for plague vaccines Gaithersburg, Maryland, USA; 2004."},{"key":"10.1016\/j.vaccine.2018.11.022_b0230","first-page":"631","article-title":"Immunity in plague. Acquisitions supplied by 30 years of work on the \u201cPasteurella Pestis Ev\u201d (Girard and Robic) Strain","volume":"52","author":"Girard","year":"1963","journal-title":"Biol Med (Paris)"},{"key":"10.1016\/j.vaccine.2018.11.022_b0235","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1128\/IAI.8.6.876-881.1973","article-title":"Pathogenicity and immunogenic efficacy of a live attentuated plaque vaccine in vervet monkeys","volume":"8","author":"Hallett","year":"1973","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.022_b0240","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/S0264-410X(02)00119-6","article-title":"Determination of the virulence of the pigmentation-deficient and pigmentation-\/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague","volume":"20","author":"Welkos","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0245","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CDLI.4.5.587-591.1997","article-title":"Field evaluation of an immunoglobulin G anti-F1 enzyme-linked immunosorbent assay for serodiagnosis of human plague in Madagascar","volume":"4","author":"Rasoamanana","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.11.022_b0250","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1016\/j.vaccine.2011.06.119","article-title":"Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines","volume":"29","author":"Quenee","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0255","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.vaccine.2009.01.050","article-title":"A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague","volume":"27","author":"Chichester","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0260","doi-asserted-by":"crossref","first-page":"7748","DOI":"10.1016\/j.vaccine.2010.09.062","article-title":"Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)","volume":"28","author":"Fellows","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.022_b0265","series-title":"Vaccine design methods in molecular biology","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-3387-7_27","article-title":"Assessment of live plague vaccine candidates","author":"Feodorova","year":"2016"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T08:05:20Z","timestamp":1694073920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18315457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0264410X18315457"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}